Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Work In Process (2016)

NovaBay Pharmaceuticals (NBY) has disclosed Work In Process for 3 consecutive years, with $27000.0 as the latest value for Q2 2016.

  • On a quarterly basis, Work In Process fell 85.33% to $27000.0 in Q2 2016 year-over-year; TTM through Jun 2016 was $27000.0, a 85.33% decrease, with the full-year FY2015 number at $248000.0, up 34.78% from a year prior.
  • Work In Process was $27000.0 for Q2 2016 at NovaBay Pharmaceuticals, down from $114000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $248000.0 in Q4 2015 to a low of $27000.0 in Q2 2016.
  • A 3-year average of $165285.7 and a median of $184000.0 in 2014 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: skyrocketed 34.78% in 2015, then plummeted 85.33% in 2016.
  • NovaBay Pharmaceuticals' Work In Process stood at $184000.0 in 2014, then surged by 34.78% to $248000.0 in 2015, then crashed by 89.11% to $27000.0 in 2016.
  • Per Business Quant, the three most recent readings for NBY's Work In Process are $27000.0 (Q2 2016), $114000.0 (Q1 2016), and $248000.0 (Q4 2015).